Page 127 - GPD-4-2

Gene & Protein in Disease Pediatric glioma circadian clock genes

47. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma doi: 10.1016/j.ccr.2014.02.004
comprises four distinct molecular variants. J Clin Oncol. 58. Singh JA, Siddiqi M, Parameshwar P, Chandra-Mouli V.
2011;29(11):1408-1414.
World Health Organization guidance on ethical
doi: 10.1200/JCO.2009.27.4324 considerations in planning and reviewing research studies
on sexual and reproductive health in adolescents. J Adolesc
48. Speir ML, Bhaduri A, Markov NS, et al. UCSC cell Health. 2019;64(4):427-429.
browser: Visualize your single-cell data. Bioinformatics.
2021;37(23):4578-4580. doi: 10.1016/j.jadohealth.2019.01.008
doi: 10.1093/bioinformatics/btab503 59. Masri S, Kinouchi K, Sassone-Corsi P. Circadian clocks,
epigenetics, and cancer. Curr Opin Oncol. 2015;27(1):50-56.
49. Riemondy KA, Venkataraman S, Willard N, et al. Neoplastic
and immune single-cell transcriptomics define subgroup- doi: 10.1097/CCO.0000000000000153
specific intra-tumoral heterogeneity of childhood 60. Angelousi A, Kassi E, Nasiri-Ansari N, Randeva HS,
medulloblastoma. Neuro Oncol. 2022;24(2):273-286. Kaltsas GA, Chrousos GP. Clock genes and cancer
doi: 10.1093/neuonc/noab135 development in particular in endocrine tissues. Endocr Relat
Cancer. 2019;26:R305-R317.
50. DeSisto J, Donson AM, Griesinger AM, et al. Tumor and immune
cell types interact to produce heterogeneous phenotypes of doi: 10.1530/ERC-19-0094
pediatric high-grade glioma. Neuro Oncol. 2024;26(3):538-552. 61. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG.
doi: 10.1093/neuonc/noad207 Deregulated expression of the PER1, PER2 and PER3 genes
in breast cancers. Carcinogenesis. 2005;26(7):1241-1246.
51. Hoffman LM, Donson AM, Nakachi I, et al. Molecular sub-
group-specific immunophenotypic changes are associated doi: 10.1093/carcin/bgi075
with outcome in recurrent posterior fossa ependymoma. 62. Fan W, Chen X, Li C, Chen L, Liu P, Chen Z. The analysis of
Acta Neuropathol. 2014;127(5):731-745. deregulated expression and methylation of the PER2 genes
doi: 10.1007/s00401-013-1212-8 in gliomas. J Cancer Res Ther. 2014;10(3):636-640.
52. Witt H, Mack SC, Ryzhova M, et al. Delineation of two doi: 10.4103/0973-1482.138202
clinically and molecularly distinct subgroups of posterior 63. Zhang J, Zhu B, Liu Y, et al. High expression of circadian
fossa ependymoma. Cancer Cell. 2011;20(2):143-157. gene mPer2 diminishes radiosensitivity of tumor cells.
doi: 10.1016/j.ccr.2011.07.007 Cancer Biother Radiopharm. 2008;23(5):561-570.
53. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver doi: 10.1089/cbr.2008.0496
mutations in histone H3.3 and chromatin remodelling genes 64. Slat EA, Sponagel J, Marpegan L, et al. Cell-intrinsic, Bmal1-
in paediatric glioblastoma. Nature. 2012;482(7384):226-231. dependent circadian regulation of temozolomide sensitivity
doi: 10.1038/nature10833 in glioblastoma. J Biol Rhythms. 2017;32(2):121-129.
54. de Bont JM, Kros JM, Passier MM, et al. Differential doi: 10.1177/0748730417696788
expression and prognostic significance of SOX genes in 65. Puram RV, Kowalczyk MS, de Boer CG, et al. Core circadian
pediatric medulloblastoma and ependymoma identified by clock genes regulate leukemia stem cells in AML. Cell.
microarray analysis. Neuro Oncol. 2008;10(5):648-660. 2016;165(2):303-316.
doi: 10.1215/15228517-2008-032 doi: 10.1016/j.cell.2016.03.015
55. Mitsui S, Yamaguchi S, Matsuo T, Ishida Y, Okamura H. 66. Wagner PM, Sosa Alderete LG, Gorne LD, et al. Proliferative
Antagonistic role of E4BP4 and PAR proteins in the circadian glioblastoma cancer cells exhibit persisting temporal control of
oscillatory mechanism. Genes Dev. 2001;15(8):995-1006. metabolism and display differential temporal drug susceptibility
doi: 10.1101/gad.873501 in chemotherapy. Mol Neurobiol. 2019;56(2):1276-1292.
56. Kool M, Korshunov A, Remke M, et al. Molecular subgroups doi: 10.1007/s12035-018-1152-3
of medulloblastoma: An international meta-analysis of 67. Lellupitiyage Don SS, Lin HH, Furtado JJ, Qraitem M,
transcriptome, genetic aberrations, and clinical data of Taylor SR, Farkas ME. Circadian oscillations persist in
WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta low malignancy breast cancer cells. Cell Cycle. 2019;
Neuropathol. 2012;123(4):473-484. 18(19):2447-2453.
doi: 10.1007/s00401-012-0958-8 doi: 10.1080/15384101.2019.1648957
57. Kool M, Jones DT, Jager N, et al. Genome sequencing of 68. Fuhr L, El-Athman R, Scrima R, et al. The circadian clock
SHH medulloblastoma predicts genotype-related response regulates metabolic phenotype rewiring via HKDC1
to smoothened inhibition. Cancer Cell. 2014;25(3):393-405. and modulates tumor progression and drug response in

Volume 4 Issue 2 (2025) 21 doi: 10.36922/gpd.4112